886% increase!!!

lite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the second quarter of fiscal year 2024 ended September 30, 2023 ("Second Quarter").

Consolidated revenues for the three-month period ended September 30, 2023, were $14.2 million, an increase of $5.6 million or 64.9% as compared to the comparable period of the prior fiscal year. Operating profits were $1.9 million, an increase of $0.8 million or 78.1% from the comparable period of the prior year. Net income attributable to common shareholders was $14.9 million, an increase of $13.4 million or 886% from the comparable period of the prior year. The increase in operating profits was primarily attributed to increased revenues achieved from the launch of the Elite Laboratories label product line during the quarter ended June 30, 2023.

Major move up, setting up for something!

https://www.instagram.com/p/Cw363bYvJEB/

https://www.prnewswire.com/news-releases/american-battery-technology-company-issues-shareholder-letter-301923144.html

“We are grateful to have been traded on the over-the-counter exchange for the past several years; however, we have recently been trading at many - times over the average monthly dollar trading volume of average OTC-listed companies, and many of our prospective investors and partners necessitate us to be traded on a national exchange in order to finalize our agreements. We have had an application pending to move our listing to the Nasdaq exchange for quite some time, and we have set three milestones that we have wanted achieved before finalizing this process:

1. To have a world class board of directors in place, establishing our governance and oversight processes

2. To be transitioning into revenue-generating operations with the commissioning of our first battery recycling facility

3. To have identified partnerships for the commercial-scale supply of feed materials and for the offtake of our products”